UK contributes £1billion to Global Fund to Fight AIDS, Tubercolosis and Malaria

IVCC today commended the United Kingdom following the announcement that the UK will contribute £1billion (US $1.6 billion) over the next three years to The Global Fund to Fight AIDS, Tubercolosis and Malaria.

Dr Nick Hamon, CEO of IVCC, said that this was a major contribution to saving lives and improving health amongst some of the poorest people in the world. 'Malaria causes over 660,000 deaths each year, mainly amongst children under the age of five, and more than 216 million people are stricken with the disease. This generous commitment by the UK will unlock substantial additional funds that will go a long way towards seeing the end of this debilitating disease.'

This contribution to the Global Fund is part of the UK Government's commitment to combating diseases that place an enormous burden on the world's poor by supporting and developing technologies that improve the health of the poorest people through better treatment and prevention. Earlier this year the Department for International Development, which leads the UK's efforts to end extreme poverty, awarded IVCC £12 million to support the development of new insecticides to combat malaria.

Since it was formed in 2005 with support from the Bill and Melinda Gates Foundation, IVCC has worked with some of the world's leading agrochemical companies to identify new active ingredients that will form the basis of totally new insecticide solutions for malaria prevention, and ultimately help to bring about the eradication of the disease. Companies partnering with IVCC have recently introduced two new insecticide formulations that prolong the effective life of current interventions and are proving to be valuable additional tools for malaria prevention.

 

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds artemisinin resistance in African children with severe malaria